99.55 +0.27 (0.27%)
After hours: 6:10PM EDT
|Bid||99.56 x 1400|
|Ask||99.80 x 800|
|Day's Range||98.74 - 103.73|
|52 Week Range||92.56 - 141.86|
|Beta (3Y Monthly)||1.78|
|PE Ratio (TTM)||16.82|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Alexion Pharmaceuticals, Inc. (ALXN) today announced that the U.S. Food and Drug Administration (FDA) approved ULTOMIRIS® (ravulizumab-cwvz) for the treatment of atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy (TMA) for adult and pediatric (one month of age and older) patients. Atypical HUS is an ultra-rare disease that can cause progressive injury to vital organs, primarily the kidneys, via damage to the walls of blood vessels and blood clots. Atypical HUS can cause sudden organ failure or a slow loss of function over time—potentially resulting in the need for a transplant, and in some cases, death.
NEW YORK , Oct. 18, 2019 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Achillion Pharmaceuticals, Inc. ("ACHN" ...
NEW YORK, Oct. 16, 2019 -- The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Achillion Pharmaceuticals, Inc..
SAN DIEGO , Oct. 16, 2019 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN) ...
Alexion Pharmaceuticals, Inc. (ALXN) today announced the appointment of Tanisha Carino, Ph.D., as Executive Vice President and the company’s first Chief Corporate Affairs Officer. Dr. Carino will join Alexion on November 4, 2019 and will serve on the company’s Executive Committee. In her role, Dr. Carino will oversee the creation of a newly integrated Corporate Affairs function that encompasses Alexion’s corporate affairs activities, including high-level relations with domestic and international governments and global communications.
Alexion Pharmaceuticals, Inc. (ALXN) and Stealth BioTherapeutics Corp (MITO) today announced an agreement for an option to co-develop and commercialize elamipretide for mitochondrial diseases. Currently being evaluated in a Phase 3 study in people with primary mitochondrial myopathy (PMM) - a genetic mitochondrial disease - elamipretide is a novel, potential first-in-class therapy that targets mitochondrial dysfunction.
Alexion Pharmaceuticals today announced that the Company will report its financial results for the third quarter ended September 30, 2019 before the US financial markets open on October 23, 2019.
Mr. Clancy and Dr. Sarin will work together in a formal transition that will occur after the filing of the company’s third quarter results, and Mr. Clancy will remain at Alexion and continue to serve as a senior advisor through the middle of 2020. “On behalf of the entire Board and executive team, I would like to thank Paul for his enormous contributions and leadership during such a critical time for the company. Over the last two years, he has played an invaluable role in our efforts to rebuild Alexion, refocus our corporate strategy and position the company for its next chapter,” said Ludwig Hantson, Ph.D., Chief Executive Officer at Alexion.
- Eidos grants Alexion exclusive license to develop and commercialize AG10 in Japan -
Alexion Pharmaceuticals today announced that management will present at the 17th Annual Morgan Stanley Global Healthcare Conference in New York, NY on Monday, September 9th, 2019 at 8:45 a.m.
NEW YORK, NY / ACCESSWIRE / July 24, 2019 / Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN ) will be discussing their earnings results in their 2019 Second Quarter Earnings to be held on July 24, 2019 at ...
Alexion Pharmaceuticals, Inc. (ALXN) today announced that the U.S. Food and Drug Administration (FDA) approved SOLIRIS® (eculizumab) for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive.1 Approximately three quarters (73%) of all patients with NMOSD test positive for anti-AQP4 auto-antibodies.2 The FDA approved SOLIRIS following an expedited six-month priority review. “Today's approval represents an important milestone for the NMOSD community,” said Victoria Jackson, co-founder of the Guthy-Jackson Charitable Foundation (GJCF), a non-profit organization dedicated to funding research and raising awareness about NMOSD.
Alexion Pharmaceuticals, Inc. (ALXN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review the company’s supplemental Biologics License Application (sBLA) for ULTOMIRIS® (ravulizumab-cwvz), the company’s long-acting C5 complement inhibitor, for the treatment of people with atypical hemolytic uremic syndrome (aHUS) in order to inhibit complement-mediated thrombotic microangiopathy (TMA). The FDA has set a target action date of October 19, 2019 under the Prescription Drug User Fee Act (PDUFA). The sBLA is based on previously announced results, which were recently presented at the European Renal Association – European Dialysis and Transplant Association (ERA-EDTA) Congress, from the Phase 3 study of ULTOMIRIS in people with aHUS, which met the primary endpoint of complete TMA response, defined by hematologic normalization and improved kidney function.
Alexion Pharmaceuticals, Inc. (ALXN) today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved ULTOMIRIS® (ravulizumab), the first and only long-acting C5 complement inhibitor administered every eight weeks, for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH).
LOS ANGELES , May 23, 2019 /PRNewswire/ -- Wedbush Securities is pleased to announce that Senior Vice President of Equity Research, Laura Chico , Ph.D., initiates coverage on six stocks in the Healthcare ...
Alexion Pharmaceuticals today announced that management will present at the RBC Capital Markets Annual Healthcare Conference in New York, NY on Tuesday, May 21, 2019 at 9:30 a.m.